Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent Signaling

• Published in: Cancers 2021-05, Vol.13 (10), p.2329
• Main Authors: Errico, Andrea, Stocco, Anna, Riccardi, Vincent M., Gambalunga, Alberto, Bassetto, Franco, Grigatti, Martina, Ferlosio, Amedeo, Tadini, Gianluca, Garozzo, Debora, Ferraresi, Stefano, Trevisan, Andrea, Giustini, Sandra, Rasola, Andrea, Chiara, Federica
• Format: Article
• Language: English
• Subjects: AKT protein; Cancer therapies; Cell culture; Collagen; Colonies; Cooperation; Cooperativity; Extracellular matrix; Extracellular signal-regulated kinase; Fibroblasts; Focal adhesion kinase; Genetic disorders; Growth factors; Heterozygosity; Loss of heterozygosity; Malignancy; MEK inhibitors; Microenvironments; Mimicry; Molecular modelling; Nervous system; Neurofibromatosis; Neurofibromin 1; Neurological disorders; Peripheral nerves; Phosphorylation; Proteins; Ras protein; Recklinghausen's disease; Schwann cells; Signal transduction; Stromal cells; Therapeutic targets; Tumor cells; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13102329

Plexiform neurofibromas (Pnfs) are benign peripheral nerve sheath tumors that are major features of the human genetic syndrome, neurofibromatosis type 1 (NF1). Pnfs are derived from Schwann cells (SCs) undergoing loss of heterozygosity (LOH) at the NF1 locus in an NF1+/− milieu and thus are variably lacking in the key Ras-controlling protein, neurofibromin (Nfn). As these SCs are embedded in a dense desmoplastic milieu of stromal cells and abnormal extracellular matrix (ECM), cell–cell cooperativity (CCC) and the molecular microenvironment play essential roles in Pnf progression towards a malignant peripheral nerve sheath tumor (MPNST). The complexity of Pnf biology makes treatment challenging. The only approved drug, the MEK inhibitor Selumetinib, displays a variable and partial therapeutic response. Here, we explored ECM contributions to the growth of cells lacking Nfn. In a 3D in vitro culture, NF1 loss sensitizes cells to signals from a Pnf-mimicking ECM through focal adhesion kinase (FAK) hyperactivation. This hyperactivation correlated with phosphorylation of the downstream effectors, Src, ERK, and AKT, and with colony formation. Expression of the GAP-related domain of Nfn only partially decreased activation of this signaling pathway and only slowed down 3D colony growth of cells lacking Nfn. However, combinatorial treatment with both the FAK inhibitor Defactinib (VS-6063) and Selumetinib (AZD6244) fully suppressed colony growth. These observations pave the way for a new combined therapeutic strategy simultaneously interfering with both intracellular signals and the interplay between the various tumor cells and the ECM.